INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of...
October 12 2018 - 6:00AM
INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the
development, manufacture and commercialization of pharmaceutical
cannabinoids and spray technology, today announced that its
collaboration with the Center for Medicinal Cannabis Research
(CMCR) at the University of California (UC) San Diego School of
Medicine has added a third study.
This additional study will evaluate the pharmacological effects
of cannabidiol (CBD) oral solution from INSYS on anxiety
associated with anorexia nervosa in adult patients. The previous
two collaborative CMCR studies, announced earlier this year, will
focus on CBD in the treatment of severe symptoms of autism in
pediatric patients and early psychosis in adult patients. The IND
(investigational new drug) application for the autism study is on
track for filing in the fourth quarter of 2018.
Separately, INSYS has initiated three clinical trials of its CBD
oral solution—for childhood absence epilepsy (Phase 2), infantile
spasms (Phase 3) and Prader-Willi syndrome (Phase 2)—and is
actively considering others as a sponsor or collaborator. In
addition, the company continues to support an ongoing study of CBD
as a potential treatment for cocaine dependence with the University
of Montreal and the Canadian Institutes of Health Research.
“Anorexia nervosa is difficult to treat and, in some cases, may
be a fatal condition,” said Emily Gray, MD, clinical assistant
professor of psychiatry at UC San Diego. “There is preliminary
research that suggests cannabinoids may be beneficial in treating
this and other eating disorders. The administration of CBD is of
interest because of the possibility that this drug might reduce
anxiety, and perhaps normalize reward and motivation. The UC San
Diego Eating Disorders Center has been at the forefront of
understanding the neurobiology of these diseases and looks forward
to further investigating.”
INSYS has a state-of-the-art manufacturing facility with unique
capabilities to produce pharmaceutical-grade cannabinoids,
including CBD.
“With three CMCR studies of our CBD oral solution already
planned, this collaboration has contributed to our momentum,” said
Saeed Motahari, president and chief executive officer of INSYS
Therapeutics. “We also look forward to reporting the results of our
company-sponsored CBD trials.”
CMCR Director Igor Grant, MD, professor and chair of the
psychiatry department at the UC San Diego School of Medicine,
added: “Cannabinoids, and cannabidiol specifically, have generated
much excitement as promising new avenues of treatment, but much
needs to be learned about their indications, efficacy and
limitations. This study in adult patients with anorexia nervosa
moves to fill critical knowledge gaps.”
More information on these and other CMCR studies is online at
https://www.cmcr.ucsd.edu/.
About CMCR
Established in 2000, the UC San Diego Center for Medicinal
Cannabis Research (CMCR) has been at the forefront of advancing
science and policy relating to the potential clinical benefits and
limitations of cannabis and cannabinoids as medicine. CMCR
initiated the first therapeutic studies using smoked cannabis in
over 20 years, completed key studies regarding the short-term
benefits of cannabis for the treatment of neuropathic pain and
spasticity, and has numerous active research projects.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that
develops and commercializes innovative drugs and novel drug
delivery systems of therapeutic molecules that improve patients’
quality of life. Using proprietary spray technology and
capabilities to develop pharmaceutical cannabinoids, INSYS is
developing a pipeline of products intended to address unmet medical
needs and the clinical shortcomings of existing commercial
products. INSYS is committed to developing medications for
potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome,
opioid addiction and overdose, and other disease areas with a
significant unmet need.
Forward-Looking Statements
This news release contains forward-looking statements regarding
the potential for the company’s CBD oral solution to become a
treatment for symptoms of anorexia nervosa, autism, early psychosis
and cocaine dependence, as well childhood absence epilepsy,
infantile spasms and Prader-Willi syndrome. These forward-looking
statements are based on management’s expectations and assumptions
as of the date of this news release; actual results may differ
materially from those in these forward-looking statements as a
result of various factors, many of which are beyond our control.
These factors include, but are not limited to, risk factors
described in our filings with the United States Securities and
Exchange Commission, including those factors discussed under the
caption “Risk Factors” in our Annual Report on Form 10-K for the
year ended Dec. 31, 2017 and subsequent updates that may occur in
our Quarterly Reports on Form 10-Q. Forward-looking statements
speak only as of the date of this news release, and we undertake no
obligation to publicly update or revise these statements, except as
may be required by law.
CONTACT:
Corporate CommunicationsJoe McGrathINSYS
Therapeutics480-500-3101jmcgrath@insysrx.com
Investor RelationsJackie Marcus or Chris
HodgesAlpha IR Group312-445-2870INSY@alpha-ir.com
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Mar 2024 to Apr 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2023 to Apr 2024